The myotonic dystrophies: Diagnosis and management

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 4, 2010, Pages 358-367

  Turner, Chris ^a   Hilton Jones, David ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BENZODIAZEPINE DERIVATIVE; CALCIUM ANTAGONIST; CHLORIDE CHANNEL; CHLORIDE CHANNEL 1; CLOMIPRAMINE; COLESTYRAMINE; COMPLEMENTARY RNA; CREATINE KINASE; CREATINE PHOSPHATE; DEXAMPHETAMINE; ERYTHROMYCIN; HAMMERHEAD RIBOZYME; IMIPRAMINE; IMMUNOGLOBULIN G; MECASERMIN RINFABATE; METHYLPHENIDATE; MEXILETINE; MODAFINIL; MYOTONIC DYSTROPHY PROTEIN KINASE; NORFLOXACIN; PHENYTOIN; PRASTERONE; PREDNISOLONE; PROCAINAMIDE; TAURINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 9;

3' UNTRANSLATED REGION; ALLELE; ANTISENSE THERAPY; ANXIETY; ARTIFICIAL HEART PACEMAKER; CATARACT EXTRACTION; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CLINICAL NURSE SPECIALIST; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DEFIBRILLATOR; DEPRESSION; DISEASE SEVERITY; DNA DETERMINATION; DNA REPAIR; DYSPHAGIA; DYSTROPHY; ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; ENDOCRINE DISEASE; EXERCISE; GASTROINTESTINAL DISEASE; GENE MUTATION; GENE SILENCING; GENE THERAPY; GENERAL ANESTHESIA; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; GENOTYPE PHENOTYPE CORRELATION; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HOLTER MONITORING; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INSULIN SENSITIVITY; MUSCLE BIOPSY; MUSCLE CONTRACTION; MUSCLE HYPOTONIA; MUSCLE MASS; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOTONIA; MYOTONIC DYSTROPHY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PARENTERAL NUTRITION; PATHOGENESIS; PHYSIOTHERAPY; POLYMERASE CHAIN REACTION; PREGNANCY; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROXIMAL MYOTONIC MYOPATHY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; SCREENING; SKIN DISCOLORATION; SLEEP DISORDERED BREATHING; SOUTHERN BLOTTING; SPEECH THERAPY; SUBCAPSULAR CATARACT; TACHYCARDIA; TRINUCLEOTIDE REPEAT; WEAKNESS;

EID: 77950604502     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.158261     Document Type: Review

References (104)

1. Harper PS. Myotonic dystrophy, 3rd edn. London: Saunders, 2001.
2. Yotova V, Labuda D, Zietkiewicz E, et al. Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec. Hum Genet 2005;117:177-87.
3. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3-prime end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
4. Harris S, Moncrieff C, Johnson K. Myotonic dystrophy: will the real gene please step forward! Hum Mol Genet 1996;5 Spec No:1417-23.
5. Martorell L, Monckton DG, Sanchez A, et al. Frequency and stability of the myotonic dystrophy type 1 premutation. Neurology 2001;56:328-35.
6. International Myotonic Dystrophy Consortium (IDMC). New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). Neurology 2000;54:1218-21.
7. de Die-Smulders CE, Land JA, Dreesen JC, et al. Results from 10 years of preimplantation-genetic diagnostics in The Netherlands. Ned Tijdschr Geneeskd 2004;148:2491-6.
8. de Temmerman N, Sermon K, Seneca S, et al. Intergenerational instability of the expanded CTG repeat in the DMPK gene: studies in human gametes and preimplantation embryos. Am J Hum Genet 2004;75:325-9.
9. Rakocevic-Stojanovic V, Savic D, Pavlovic S, et al. Intergenerational changes of CTG repeat depending on the sex of the transmitting parent in myotonic dystrophy type 1. Eur J Neurol 2005;12:236-7.
10. Zeesman S, Carson N, Whelan DT. Paternal transmission of the congenital form of myotonic dystrophy type 1: a new case and review of the literature. Am J Med Genet 2002;107:222-226
11. Brunner HG, Bruggenwirth HT, Nillesen W, et al. Influence of sex of the transmitting parent as well as of parental allele size on the CTG expansion in myotonic dystrophy (DM). Am J Hum Genet 1993;53:1016-23.
12. de Die-Smulders CE, Smeets HJ, Loots W, et al. Paternal transmission of congenital myotonic dystrophy. J Med Genet 1997;34:930-3.
13. Dean NL, Loredo-Osti JC, Fujiwara TM, et al. Transmission ratio distortion in the myotonic dystrophy locus in human preimplantation embryos. Eur J Hum Genet 2006;14:299-306.
14. Gharehbaghi-Schnell EB, Finsterer J, Korschineck I, et al. Genotypeephenotype correlation in myotonic dystrophy. Clin Genet 1998;53:20-6.
15. Hamshere MG, Harley H, Harper P, et al. Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions. J Med Genet 1999;36:59-61.
16. Lavedan C, Hofmann-Radvanyi H, Shelbourne P, et al. Myotonic dystrophy: size-and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. Am J Hum Genet 1993;52:875-83.
17. Miaux Y, Chiras J, Eymard B, et al. Cranial MRI findings in myotonic dystrophy. Neuroradiology 1997;39:166-70.
18. Ashizawa T. Myotonic dystrophy as a brain disorder. Arch Neurol 1998;55:291-3.
19. Spranger M, Spranger S, Tischendorf M, et al. Myotonic dystrophy. The role of large triplet repeat length in the development of mental retardation. Arch Neurol 1997;54:251-4.
20. Joseph JT, Richards CS, Anthony DC, et al. Congenital myotonic dystrophy pathology and somatic mosaicism. Neurology 1997;49:1457-60.
21. Harper PS, Van Engelen B, Eymard B, et al. Myotonic dystrophy: present management, future therapy. Oxford: Oxford University Press, 2004:251.
22. Steyaert J, Umans S, Willekens D, et al. A study of the cognitive and psychological profile in 16 children with congenital or juvenile myotonic dystrophy. Clin Genet 1997;52:135-41.
23. Krishnan AV, Kiernan MC. Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve 2006;33:627-36.
24. Redman JB, Fenwick RG Jr, Fu YH, et al. Relationship between parental trinucleotide CTG repeat length and severity of myotonic dystrophy in offspring. JAMA 1993;269:1960-5.
25. de Die-Smulders CE, Howeler CJ, Thijs C, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998;121:1557-63.
26. Mathieu J, Allard P, Potvin L, et al. 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999;52:1658-62.
27. Cobo AM, Poza JJ, Martorell L, et al. Contribution of molecular analyses to the estimation of the risk of congenital myotonic dystrophy. J Med Genet 1995;32:105-8.
28. Logigian EL, Blood CL, Dilek N, et al. Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1. Muscle Nerve 2005;32:35-42.
29. de Swart BJ, van Engelen BG, van de Kerkhof JP, et al. Myotonia and flaccid dysarthria in patients with adult onset myotonic dystrophy. J Neurol Neurosurg Psychiatry 2004;75:1480-2.
30. Garrott HM, Walland MJ, O'Day J. Recurrent posterior capsular opacification and capsulorhexis contracture after cataract surgery in myotonic dystrophy. Clin Experiment Ophthalmol 2004;32:653-5.
31. Bassez G, Lazarus A, Desguerre I, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 2004;63:1939-41.
32. Chebel S, Ben Hamda K, Boughammoura A, et al. [Cardiac involvement in Steinert's myotonic dystrophy] (in French). Rev Neurol (Paris) 2005;161:932-9.
33. Dello Russo A, Pelargonio G, Parisi Q, et al. Widespread electroanatomic alterations of right cardiac chambers in patients with myotonic dystrophy type 1. J Cardiovasc Electrophysiol 2006;17:34-40.
34. Montella L, Caraglia M, Addeo R, et al. Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). Ann Hematol 2005;84:192-3.
35. Phillips MF, Harper PS. Cardiac disease in myotonic dystrophy. Cardiovasc Res 1997;33:13-22.
36. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688-97.
37. van Engelena B, Eymard B, Wilcox D. Workshop report:123rd ENMC International Workshop: Management and Therapy in Myotonic Dystrophy, 6-8 February 2004, Naarden, The Netherlands. Neuromuscul Disord 2005;15:389-94.
38. Parisi M, Galderisi M, Sidiropulos M, et al. Early detection of biventricular involvement in myotonic dystrophy by tissue Doppler. Int J Cardiol 2007;118:227-32.
39. Gaul C, Schmidt T, Windisch G, et al. Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006;67:350-2.
40. Modoni A, Silvestri G, Pomponi MG, et al. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004;61:1943-7.
41. Delaporte C. Personality patterns in patients with myotonic dystrophy. Arch Neurol 1998;55:635-40.
42. Winblad S, Lindberg C, Hansen S. Temperament and character in patients with classical myotonic dystrophy type 1 (DM-1). Neuromuscul Disord 2005;15:287-92.
43. Giubilei F, Antonini G, Bastianello S, et al. Excessive daytime sleepiness in myotonic dystrophy. J Neurol Sci 1999;164:60-3.
44. Rubinsztein JS, Rubinsztein DC, Goodburn S, et al. Apathy and hypersomnia are common features of myotonic dystrophy. J Neurol Neurosurg Psychiatry 1998;64:510-15.
45. van der Werf S, Kalkman J, Bleijenberg G, et al. The relation between daytime sleepiness, fatigue, and reduced motivation in patients with adult onset myotonic dystrophy. J Neurol Neurosurg Psychiatry 2003;74;138-9.
46. Heatwole CR, Miller J, Martens B, et al. Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch Neurol 2006;63:1149-53.
47. Ronnblom A, Forsberg H, Danielsson A. Gastrointestinal symptoms in myotonic dystrophy. Scand J Gastroenterol 1996;31:654-7.
48. Ronnblom A, Andersson S, Hellstrom PM, et al. Gastricemptying in myotonic dystrophy. Eur J Clin Invest 2002;32:570-4.
49. Garcia de Andoin N, Echeverria J, Cobo AM, et al. A neonatal form of Steinert's myotonic dystrophy in twins after in vitro fertilization. Fertil Steril 2005;84:756.
50. Barbosa J, Nuttall FQ, Kennedy W, et al. Plasma insulin in patients with myotonic dystrophy and their relatives. Medicine (Baltimore) 1974;53:307-23.
51. Jakase S, Okita N, Sakuma H, et al. Endocrinological abnormalities in myotonic dystrophy: consecutive studies of eight tolerance tests in 26 patients. Tohoky J Exp Med 1987;153:355-74.
52. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001;29:40-7.
53. Cigliano B, Baltogiannis N, De Marco M, et al. Pilomatricoma in childhood: a retrospective study from three European paediatric centres. Eur J Pediatr 2005;164:673-7.
54. Geh JL, Moss AL. Multiple pilomatrixomata and myotonic dystrophy: a familial association. Br J Plast Surg 1999;52:143-5.
55. Howard RS, Wiles CM, Hirsch NP, et al. Respiratory involvement in primary muscle disease: assessment and management. Q J Med 1993;86:175-89.
56. Antonini G, Soscia F, Giubilei F, et al. Health related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. J Rehabil Med 2006;38:181-5.
57. Whittaker RG, Ferenczi E, Hilton-Jones D. Myotonic dystrophy: practical issues relating to assessment of strength. J Neurol Neurosurg Psychiatry 2006;77:1282-3.
58. Sarnat HB, O'Connor T, Byrne PA. Clinical effects of myotonic dystrophy on pregnancy and the neonate. Arch Neurol 1976;33:459-65.
59. Webb D, Muir I, Faulkner J, et al. Myotonia dystrophica: obstetric complications. Am J Obstet Gynecol 1978;132:265-70.
60. Mathieu J, Allard P, Gobeil G, et al. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 1997;49:1646-50.
61. Nishi M, Itoh H, Tsubokawa T, et al. Effective doses of vecuronium in a patient with myotonic dystrophy. Anaesthesia 2004;59:1216-18.
62. Arsenault ME, Prevost C, Lescault A, et al. Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 2006;66:1248-50.
63. Maurage CA, Udd B, Ruchoux MM, et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005;65:1636-8.
64. Oyamada R, Hayashi M, Katoh Y, et al. Neurofibrillary tangles and deposition of oxidative products in the brain in cases of myotonic dystrophy. Neuropathology 2006;26:107-14.
65. Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003;60:657-64.
66. Day JW, Roelofs R, Leroy B, et al. Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). Neuromuscul Disord 1999;9:19-27.
67. Meola G, Sansone V, Radice S, et al. A family with an unusual myotonic and myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): a challenge for future molecular studies. Neuromuscul Disord 1996;6:143-50.
68. Udd B, Krahe R, Wallgren-Pettersson C, et al. Proximal myotonic dystrophyda family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord 1997;7:217-28.
69. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-7.
70. Ricker K, Grimm T, Koch MC, et al. Linkage of proximal myotonic myopathy to chromosome 3q. Neurology 1999;52:170-1.
71. Mankodi A, Takahashi MP, Jiang H, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002;10:35-44.
72. Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004;74:793-804.
73. Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 2005;15:5-16.
74. Kanadia RN, Johnstone KA, Mankodi A, et al. A muscleblind knockout model for myotonic dystrophy. Science 2003;302:1978-80.
75. Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005;32:1-18.
76. Le Ber I, Martinez M, Campion D, et al. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Brain 2004;127:1979-92.
77. th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006;16:403-13.
78. Carter JN, Steinbeck KS. Reduced adrenal androgens in patients with myotonic dystrophy. J Clin Endocrinol Metab 1985;60:611-14.
79. Nakazora H, Kurihara T. The effect of dehydroepiandrosterone sulfate (DHEAS) on myotonia: intracellular studies. Intern Med 2005;44:1247-51.
80. Sugino M, Ohsawa N, Ito T, et al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51:586-9.
81. Pénisson-Besnier I, Devillers M, Porcher R, et al. Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology 2008;71:407-12.
82. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005;6:743-55.
83. Furlin D, Marette A, Puymirat J. Insulin-like growth factor I circumvents defective insulin action in human myotonic dystrophy skeletal muscle cells. Endocrinology 1999;140:4244-50.
84. Winn N, Paul A, Musaŕo A, et al. Insulin-like growth factor isoforms in skeletal muscle aging, regeneration, and disease. Cold Spring Harb Symp Quant Biol 2003;67:507-18.
85. Walter MC, Reilich P, Lochm̈uller H, et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol 2002;249:1717-22.
86. Tarnopolsky M, Mahoney D, Thompson T, et al. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve 2004;29:51-8.
87. Kley RA, Vorgerd M, Tarnopolsky MA. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2007;1:CD004760.
88. Schneider-Gold C, Beck M, Wessig C, et al. Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy. Neurology 2003;60:500-2.
89. van der Kooi EL, Lindeman E, Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2010:CD003907.
90. Lindeman E, Leffers P, Spaans F, et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil 1995;76:612-20.
91. Trip J, Drost GG, van Engelen BGM, et al. Drug treatment for myotonia. Cochrane Database Syst Rev 2007;4:CD004762.
92. Lazarus A, Varin J, Ounnoughene Z, et al. Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:1041-6.
93. MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002;59:1876-80.
94. Talbot K, Stradling J, Crosby J, et al. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord 2003;13:357-64.
95. Wintzen AR, Lammers GJ, van Dijk JG. Does modafinil enhance activity of patients with myotonic dystrophy? A double-blind placebo-controlled crossover study. J Neurol 2007;254:26-28.
96. Damian MS, Gerlach A, Schmidt F, et al. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001;56:794-6.
97. Annane D, Moore DH, Barnes PRJ, et al. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. Cochrane Database Syst Rev 2006:3: CD003218.
98. Motlagh B, MacDonald JR, Tarnopolsky MA. Nutritional inadequacy in adults with muscular dystrophy. Muscle Nerve 2005;31:713-18.
99. Marc-André L, Nan Sook L, Rossi JJ, et al. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther 1999;7:670-80.
100. Furling D, Doucet G, Langlois MA, et al. Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther 2003;10:795-802.
101. Cooper TA. A reversal of misfortune for myotonic dystrophy? N Engl J Med 2006;355:1825-7.
102. Kanadia RN, Shin J, Yuan Y, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA 2006;103:11748-53.
103. Mahadevan MS, Yadava RS, Yu Q, et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006;38:1066-70.
104. Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007;117:3952-7.